The OSUCCC – James is home to an internationally renowned center for hematologic malignancy treatment and research. Transdisciplinary teams of hematologists, oncologists, mid-level practitioners, researchers, nurses and other experts specialize in distinct hematologic malignancies, including:
- Acute myeloid leukemia (AML)
- Acute lymphoblastic leukemia (ALL)
- Blood and marrow transplantation
- Chronic lymphocytic leukemia (CLL)
- Hairy cell leukemia
- Myeloproliferative disorders
- Multiple myeloma
- Hodgkin lymphoma
- Non-Hodgkin lymphoma
Ohio State’s distinguished history in leukemia research began in 1958, when Dr. Bertha Bouroncle identified the cell responsible for hairy cell leukemia, a rare chronic leukemia.
Today, millions of dollars in research grants, including multiple grants from the National Cancer Institute and from the Leukemia and Lymphoma Society, support OSUCCC – James studies into how blood cancers develop and into identifying promising investigational treatments.
Hundreds of clinical trials under way at the OSUCCC – James enable us to provide patients with the latest advances in detecting and treating hematologic malignancies.